256 related articles for article (PubMed ID: 17873138)
21. Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies.
Vriens D; de Geus-Oei LF; van Laarhoven HW; Timmer-Bonte JN; Krabbe PF; Visser EP; Oyen WJ
Nucl Med Commun; 2009 Jul; 30(7):550-7. PubMed ID: 19424100
[TBL] [Abstract][Full Text] [Related]
22. Early detection of disease progression after palliative chemotherapy in NSCLC patients by (18)F-FDG-PET.
Tauhardt E; Reissig A; Winkens T; Freesmeyer M
Nuklearmedizin; 2014; 53(5):197-204. PubMed ID: 24986272
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
Hellwig D; Gröschel A; Graeter TP; Hellwig AP; Nestle U; Schäfers HJ; Sybrecht GW; Kirsch CM
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):13-21. PubMed ID: 16151765
[TBL] [Abstract][Full Text] [Related]
24. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
Tiseo M; Ippolito M; Scarlattei M; Spadaro P; Cosentino S; Latteri F; Ruffini L; Bartolotti M; Bortesi B; Fumarola C; Caffarra C; Cavazzoni A; Alfieri RR; Petronini PG; Bordonaro R; Bruzzi P; Ardizzoni A; Soto Parra HJ
Cancer Chemother Pharmacol; 2014 Feb; 73(2):299-307. PubMed ID: 24258456
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic value of (18)F-fluorodeoxyglucose uptake in patients with non-small cell lung cancer treated by concurrent chemoradiotherapy].
Zhang HQ; Yu JM; Meng X; Yue JB; Feng R; Ma L
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):603-6. PubMed ID: 21122413
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
[TBL] [Abstract][Full Text] [Related]
27. Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Valdés Olmos RA; van Pel R; Burgers SA; van Tinteren H; Klomp HM;
J Nucl Med; 2014 Jul; 55(7):1081-6. PubMed ID: 24812245
[TBL] [Abstract][Full Text] [Related]
28. Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography.
Tsuchida T; Morikawa M; Demura Y; Umeda Y; Okazawa H; Kimura H
J Magn Reson Imaging; 2013 Jul; 38(1):80-8. PubMed ID: 23239463
[TBL] [Abstract][Full Text] [Related]
29. Limited Prognostic Value of SUV max Measured by F-18 FDG PET/CT in Newly Diagnosed Small Cell Lung Cancer Patients.
Kim SJ; Chang S
Oncol Res Treat; 2015; 38(11):577-85. PubMed ID: 26599271
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
[TBL] [Abstract][Full Text] [Related]
31. Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer.
Li L; Hu M; Zhu H; Zhao W; Yang G; Yu J
Clin Lung Cancer; 2010 Sep; 11(5):335-40. PubMed ID: 20837459
[TBL] [Abstract][Full Text] [Related]
32. Prognostic stratification using F-18 FDG PET/CT in patients with advanced stage (stage III and IV) non-small cell lung cancer.
Kim YS; Lee MK; Kim SJ; Kim IJ; Kim YK; Jo WS; Park SK
Neoplasma; 2010; 57(3):241-6. PubMed ID: 20353275
[TBL] [Abstract][Full Text] [Related]
33. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
[TBL] [Abstract][Full Text] [Related]
34. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.
Nestle U; Kremp S; Schaefer-Schuler A; Sebastian-Welsch C; Hellwig D; Rübe C; Kirsch CM
J Nucl Med; 2005 Aug; 46(8):1342-8. PubMed ID: 16085592
[TBL] [Abstract][Full Text] [Related]
35. Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response.
Obrzut S; Bykowski J; Badran K; Hayeri MR; Hoh CK
Nucl Med Commun; 2010 Dec; 31(12):1008-15. PubMed ID: 20926977
[TBL] [Abstract][Full Text] [Related]
36. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Langen HJ; Bares R
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):463-71. PubMed ID: 17103167
[TBL] [Abstract][Full Text] [Related]
37. Higher predictive value of tumour and node [18F]-FDG PET metabolic volume and TLG in advanced lung cancer under chemotherapy.
Olivier A; Petyt G; Cortot A; Scherpereel A; Hossein-Foucher C
Nucl Med Commun; 2014 Sep; 35(9):908-15. PubMed ID: 24785008
[TBL] [Abstract][Full Text] [Related]
38. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery.
Kalff V; Duong C; Drummond EG; Matthews JP; Hicks RJ
J Nucl Med; 2006 Jan; 47(1):14-22. PubMed ID: 16391182
[TBL] [Abstract][Full Text] [Related]
39. Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic
Meijer TWH; de Geus-Oei LF; Visser EP; Oyen WJG; Looijen-Salamon MG; Visvikis D; Verhagen AFTM; Bussink J; Vriens D
Radiology; 2017 May; 283(2):547-559. PubMed ID: 27846378
[TBL] [Abstract][Full Text] [Related]
40. Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
Novello S; Vavalà T; Levra MG; Solitro F; Pelosi E; Veltri A; Scagliotti GV
Clin Lung Cancer; 2013 May; 14(3):230-7. PubMed ID: 23276821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]